ZYVERSA THERAPEUTICS, INC. Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
ZYVERSA THERAPEUTICS, INC. (ZVSA) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $91.25 million as of 2023-06-30, per its 10-K filed 2024-03-25.
Discontinued › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2024-03-25
- 2023-06-30: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $91.25M.
- 2022-12-31: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $91.25M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net |
|---|---|
| 2023-06-30 | $91.25M 10-K · filed 2024-03-25 |
| 2022-12-31 | $91.25M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |